Five things for pharma marketers to know: Tuesday, March 7, 2017

Share this content:

1. President Trump tweeted that he's working on a new pricing system for prescription drugs. “Pricing for the American people will come way down!” he wrote. (Reuters)

2. Republican lawmakers revealed their proposed replacement to the Affordable Care Act. The plan removes the ACA's penalty for people who don't buy insurance and offers a tax subsidy based on a person's age. (Vox)

3. Researchers are currently studying more than 1,100 immunotherapy drugs, up from roughly 500 two years ago, as they race to develop the next cancer immunotherapy. Analysts say global immunotherapy sales could reach more than $40 billion a year by 2025, up from $6 billion now. (WSJ)

4. Cancer patients may combat fatigue more easily with exercise than drugs, a new study published in JAMA Oncology suggests. Exercise and psychotherapy were associated with a 26% to 30% drop in fatigue during and after cancer treatment. (Reuters)

5. Vertex Pharmaceuticals has acquired Concert Pharmaceuticals' experimental cystic-fibrosis drug, CTP-656, for $160 million. Concert executives said CTP-656 has the potential to be a longer-acting version of Vertex's cystic-fibrosis drug Kalydeco. (Endpts)

Share this content:
Scroll down to see the next article